BURLINGTON, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present virtually at the SVB Securities Global Biopharma Conference, on Thursday, February 16 at 11:20 am ET. Mr. Tucker will also be meeting virtually with investors on that day.
To arrange a one-on-one meeting, please contact your SVB Securities representative.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.52 |
Daily Change: | -0.01 -0.18 |
Daily Volume: | 3,876,051 |
Market Cap: | US$294.220M |
August 14, 2025 August 07, 2025 May 14, 2025 March 19, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load